Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03411252 · ClinicalTrials.gov registry record · Early Phase 1
Mirabegron in Achalasia: A Clinical and Manometric Proof of Concept Pilot Study
A Early Phase 1 study, sponsored by Thomas Jefferson University.
- Terminated
- Registry status
- Early Phase 1
- Development phase
- 5
- Enrollment target
NCT03411252 is a Early Phase 1 study that was terminated before completion, run by Thomas Jefferson University. The registered enrollment target is 5 participants.
The verdict
NCT03411252, a Early Phase 1 study, was terminated before completion, sponsored by Thomas Jefferson University.
- TERMINATED
- Registry status
- Early Phase 1
- Development phase
- 5 participants
- Enrollment target
Study Summary
This study evaluates whether a medication called mirabegron is better than placebo (sugar pill) in helping patients with achalasia swallow better. Each patient will receive either mirabegron or the placebo for 4 weeks followed by the opposite medication. Each patient will complete several surveys and undergo several tests to determine if the mirabegron is helping reduce the pressures in the esophagus (swallowing tube).
Interventions
- DRUG Placebo
- DRUG Mirabegron 50 MG
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2018-02-15 |
| Est. Completion | 2019-12-15 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03411252
The ClinicalTrials.gov registry entry for NCT03411252 describes a study currently listed as terminated, categorized as Early Phase 1. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Thomas Jefferson University, which has 292 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03411252 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03411252 about?
NCT03411252 is a clinical study titled "Mirabegron in Achalasia: A Clinical and Manometric Proof of Concept Pilot Study". This study evaluates whether a medication called mirabegron is better than placebo (sugar pill) in helping patients with achalasia swallow better. Each patient will receive either mirabegron or the placebo for 4 weeks followed by the opposite medication. Each patient will complete several surveys an...
What is the current status of trial NCT03411252?
This trial is currently terminated. It is a Early Phase 1 study. The enrollment target is 5 participants. The study started on 2018-02-15. Estimated completion is 2019-12-15.
What interventions are being tested in trial NCT03411252?
The interventions under investigation include: Placebo (DRUG), Mirabegron 50 MG (DRUG).
Who is sponsoring clinical trial NCT03411252?
This trial is sponsored by Thomas Jefferson University, which has 292 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.